Is Palisade Bio Inc (PALI) overvalued? · P/E 15, $316.3M cap
Palisade Bio Inc (PALI) is a biotechnology company listed on NASDAQ.
This page asks whether Palisade Bio Inc (PALI) looks expensive on cached numbers — not a short thesis.
Latest reported PALI revenue for 2024-12-31 was $0. Net income was -$14.4M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. PALI currently screens at market cap $316.3M and trailing P/E 15.2.
PALI currently screens at market cap $316.3M and trailing P/E 15.2. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PALI 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PALI stock page for the full model, not this heading.
Not investment advice.